JP2024506942A - Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 - Google Patents

Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 Download PDF

Info

Publication number
JP2024506942A
JP2024506942A JP2023549823A JP2023549823A JP2024506942A JP 2024506942 A JP2024506942 A JP 2024506942A JP 2023549823 A JP2023549823 A JP 2023549823A JP 2023549823 A JP2023549823 A JP 2023549823A JP 2024506942 A JP2024506942 A JP 2024506942A
Authority
JP
Japan
Prior art keywords
hemi
compound
citrate
weight
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023549823A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506942A5 (https=
Inventor
ドリス ネヴィル
アフマド ハシャシュ
カール ハンセン
ヨハン チャン
Original Assignee
プラクシス プレシジョン メディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プラクシス プレシジョン メディシンズ， インコーポレイテッド filed Critical プラクシス プレシジョン メディシンズ， インコーポレイテッド
Publication of JP2024506942A publication Critical patent/JP2024506942A/ja
Publication of JP2024506942A5 publication Critical patent/JP2024506942A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2023549823A 2021-02-18 2022-02-16 Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態 Pending JP2024506942A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163150782P 2021-02-18 2021-02-18
US63/150,782 2021-02-18
PCT/US2022/016612 WO2022178000A1 (en) 2021-02-18 2022-02-16 Hemi-citrate salts of gaba-a positive allosteric modulator and crystalline form thereof

Publications (2)

Publication Number Publication Date
JP2024506942A true JP2024506942A (ja) 2024-02-15
JP2024506942A5 JP2024506942A5 (https=) 2025-02-25

Family

ID=82931143

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023549823A Pending JP2024506942A (ja) 2021-02-18 2022-02-16 Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態

Country Status (5)

Country Link
US (2) US20240190910A1 (https=)
EP (1) EP4294819A4 (https=)
JP (1) JP2024506942A (https=)
TW (1) TW202245790A (https=)
WO (1) WO2022178000A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
EP4514357A4 (en) * 2022-04-26 2026-04-29 Praxis Prec Medicines Inc METHODS OF TREATING NEUROLOGICAL DISORDERS

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021504297A (ja) * 2018-08-31 2021-02-15 プラクシス プレシジョン メディスンズ，インコーポレイテッドＰｒａｘｉｓ Ｐｒｅｃｉｓｉｏｎ Ｍｅｄｉｃｉｎｅｓ，Ｉｎｃ． Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004072079A1 (en) * 2003-02-11 2004-08-26 Pfizer Limited Hydrated and anhydrous sildenafil hemi-citrate compound
US20060074059A1 (en) * 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
ATE538797T1 (de) * 2005-06-09 2012-01-15 Euro Celtique Sa Pharmazeutische zusammensetzungen mit neuroaktivem steroid und verwendungen davon

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021504297A (ja) * 2018-08-31 2021-02-15 プラクシス プレシジョン メディスンズ，インコーポレイテッドＰｒａｘｉｓ Ｐｒｅｃｉｓｉｏｎ Ｍｅｄｉｃｉｎｅｓ，Ｉｎｃ． Ｇａｂａａの正のアロステリックモジュレーターの塩及び結晶形態

Also Published As

Publication number Publication date
US20240190910A1 (en) 2024-06-13
WO2022178000A1 (en) 2022-08-25
US20220289789A1 (en) 2022-09-15
TW202245790A (zh) 2022-12-01
US11697669B2 (en) 2023-07-11
EP4294819A1 (en) 2023-12-27
EP4294819A4 (en) 2024-12-18

Similar Documents

Publication Publication Date Title
US12595254B2 (en) Crystal form of Resmetirom, preparation method therefor, and use thereof
JP6028016B2 (ja) リナグリプチンベンゾエートの多形体
Wang et al. Expedited development of a high dose orally disintegrating metformin tablet enabled by sweet salt formation with acesulfame
EP2691395A1 (en) Processes for preparing tofacitinib salts
JP2024506942A (ja) Ｇａｂａ－ａポジティブアロステリック調節物質のヘミ－クエン酸塩およびその結晶形態
EP2758030A1 (en) Compressed oral dosage form for asenapine maleate
US8962675B1 (en) Atrasentan mandelate salts
AU2017254950A1 (en) Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
WO2017109772A1 (en) Amorphous form of selexipag
US20120021054A1 (en) Tablet formulation of ezatiostat
CN111527089B (zh) Acalabrutinib的新晶型及其制备方法和用途
TW202434570A (zh) 嘧啶三唑化合物之固體及共晶體形式
US20050090537A1 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
US10961235B2 (en) Crystalline form of masitinib
WO2019105359A1 (zh) Acalabrutinib的晶型及其制备方法和用途
AU2021237686B2 (en) Cocrystals of (1r,3s)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid
CN111417624B (zh) Eb-1020的晶型及其制备方法和用途
CA3288417A1 (en) Salt of benzimidazole derivative
US7595335B2 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof
US8476307B2 (en) Pharmaceutical composition based on idazoxan, salts, hydrates or polymorphs thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250818

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260220